March 25, 2026 — At the 75th Annual Scientific Session & Expo of the American College of Cardiology (ACC.26) in New Orleans, Cleerly will launch Cleerly PREVIEW, a new workflow-support enhancement designed to assist clinicians with case prioritization and streamline administrative processes, such as prior authorization, for coronary artery disease (CAD) imaging.
In addition, Cleerly will present findings from four scientific abstracts spanning plaque quantification, risk stratification, and cardiovascular outcomes, including two studies that draw on data from the CONFIRM2 Registry. CONFIRM2 is a multicenter, international, observational cohort targeting 30,000 patients, with more than 10,750 participants currently enrolled, that aims to perform comprehensive quantification of computed tomography (CT) angiography findings and relate them to clinical variables and cardiovascular clinical outcomes.
Cleerly PREVIEW
Cleerly PREVIEW is a new workflow-support enhancement to Cleerly's artificial intelligence-enabled quantitative computed tomography (AI-QCT) platform that helps clinicians prioritize cases based on potential severity of coronary artery disease while also facilitating administrative processes like the prior authorization and reimbursement pathway. Key upgrades include greatest diameter stenosis values and stenosis location information, with stenosis ranges mapped to established reimbursement thresholds.
“Cleerly PREVIEW was built to bring key stenosis data front and center. By connecting this upfront information directly to reimbursement thresholds, we're helping streamline the administrative workflow and drive efficiency in the prior authorization process," said James K. Min, founder and CEO of Cleerly.
Presentations at ACC.26
The abstract that will be presented include:
- March 28
- Sex-Based Differences in PREVENT Risk, Coronary Calcium, and Noncalcified Plaque by AI Quantitative Coronary CT
- March 29
- AI-Guided Quantitative Coronary CT for Risk Stratification of Major Adverse Cardiovascular Events in Patients with and without Diabetes: CONFIRM 2 Registry
- Advanced Imaging to Understand the Relation between Coronary Microvascular Dysfunction and Coronary Plaque Burden and Vascular Remodeling
- March 30
- Percent Atheroma Volume by CCTA with AI-QCT Identifies Thresholds for Prognostic Benefit of Revascularization: Insights from the CONFIRM 2 Registry
For times and locations of the presentations, go to https://accscientificsession.acc.org/
November 03, 2026 
